Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus.
Adamichou C, Flouri I, Fanouriakis A, Nikoloudaki M, Nikolopoulos D, Repa A, Boki K, Chatzidionysiou K, Garyfallos A, Boumpas D, Sidiropoulos P, Bertsias G. Adamichou C, et al. Among authors: nikoloudaki m. Mediterr J Rheumatol. 2020 Mar 31;31(1):87-91. doi: 10.31138/mjr.31.1.87. eCollection 2020 Mar. Mediterr J Rheumatol. 2020. PMID: 32411939 Free PMC article.
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus.
Adamichou C, Genitsaridi I, Nikolopoulos D, Nikoloudaki M, Repa A, Bortoluzzi A, Fanouriakis A, Sidiropoulos P, Boumpas DT, Bertsias GK. Adamichou C, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2021 Jun;80(6):758-766. doi: 10.1136/annrheumdis-2020-219069. Epub 2021 Feb 10. Ann Rheum Dis. 2021. PMID: 33568388 Free PMC article.
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
Moysidou GS, Garantziotis P, Sentis G, Nikoleri D, Malissovas N, Nikoloudaki M, Stergioti EM, Polia S, Paschalidis N, Filia A, Grigoriou M, Nikolopoulos D, Kapsala N, Katechis S, Fanouriakis A, Bertsias G, Boumpas DT. Moysidou GS, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2024 Nov 13:ard-2024-226051. doi: 10.1136/ard-2024-226051. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39510807 Free article.
Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study.
Pappa M, Kosmetatou M, Pieta A, Nikoloudaki M, Liapis NM, Tsalapaki C, Chalkia A, Argyriou E, Dimitroulas T, Cheila M, Demirtzoglou G, Papagoras C, Goules A, Katsiari C, Vassilopoulos D, Sidiropoulos P, Boki KA, Sfikakis PP, Liapis G, Gakiopoulou H, Voulgari PV, Boumpas DT, Bertsias G, Tektonidou MG, Fanouriakis A. Pappa M, et al. Among authors: nikoloudaki m. RMD Open. 2024 Sep 18;10(3):e004437. doi: 10.1136/rmdopen-2024-004437. RMD Open. 2024. PMID: 39299738 Free PMC article.
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.
Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N, Nikoloudaki M, Pieta A, Flouda S, Parodis I, Bertsias G, Fanouriakis A, Filia A, Boumpas DT. Nikolopoulos D, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2024 Aug 27;83(9):1132-1143. doi: 10.1136/ard-2024-225664. Ann Rheum Dis. 2024. PMID: 38609158 Free PMC article.
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment.
Dedemadi AG, Gkolfinopoulou C, Nikoleri D, Nikoloudaki M, Ruhanen H, Holopainen M, Kakela R, Christopoulou G, Bournazos S, Constantoulakis P, Sidiropoulos P, Bertsias G, Chroni A. Dedemadi AG, et al. Among authors: nikoloudaki m. Rheumatology (Oxford). 2024 Mar 21:keae192. doi: 10.1093/rheumatology/keae192. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38514392
Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides.
Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, Terizaki M, Nikoloudaki M, Eskitzis A, Kalogiannaki E, Bertsias G, Sidiropoulos P. Flouri ID, et al. Among authors: nikoloudaki m. Mediterr J Rheumatol. 2023 Jul 31;34(4):581-587. doi: 10.31138/mjr.310723.cba. eCollection 2023 Dec. Mediterr J Rheumatol. 2023. PMID: 38282943 Free PMC article.
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pitsigavdaki S, et al. Among authors: nikoloudaki m. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
13 results